Generic name (brand) |
Mechanism of action |
Uses |
Dosage/route of administration |
| Azacitidine (Vidaza®)
FDA approval 2004 |
DNMT inhibitor with possible cytotoxic effect |
Labeled: myelodysplastic syndrome (MDS)
Unlabeled: Acute Myelogenous Leukemia (AML) |
MDS: 75 mg/m2/day x 7 days (subcutaneous, IV)
Repeated every 4 week |
| Decitabine (Dacogen®)
FDA approval 2006 |
DNMT inhibitor with possible cytotoxic effect |
Labeled: MDS
Unlabeled: AML and Sickle Cell Anemia |
MDS: 15 mg/m2 every 8hrs (IV) (~45 mg/m2/day x 3 days). It is recommended to administer the drug for at least 4 cycles; continue until patient has no benefit |
| Vorinostat (Zolinza®)
FDA approval 2006 |
Histone deacetylase (HDAC) inhibitor (class 1 and 2) |
Labeled: cutaneous T-cell lymphoma (CTCL) [progression, persistent & recurrent] |
CTCL: 400 mg orally once daily (until disease progresses or unacceptable toxicity develops) |
| Romidepsin (Istodax®)
FDA approval 2009 |
HDAC inhibitor (potent class I inhibitor) |
Labeled: refractory CTCL and refractory Peripheral T-cell Lymphoma (PTCL) |
CTCL: 14 mg/m2 (IV) on days: 1, 8 and 15 in a 28-day cycle.
PTCL: 14 mg/m2 on days 1, 8, & 15 in a 28-day cycle.
(Repeat cycles as long as there is benefit & patient is tolerated) |
